Researchers have been committed to investigate effective neoadjuvant chemotherapy strategies at the molecular level, with a focus on genetic background of breast-cancer susceptibility genes such as BRCA1/2 loss-of-function mutations. This evidence concerns the gene BRCA1 and breast cancer.